Beneficial protective effect of pramipexole on light-induced retinal damage in mice

Experimental Eye Research

Volumn 139, Issue , 2015, Pages 64-72

  Shibagaki, Keiichi ^a,b   Okamoto, Kazuyoshi ^a   Katsuta, Osamu ^a   Nakamura, Masatsugu ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Age related macular degeneration; Antioxidant; Apoptosis; Light induced retinal damage; Pramipexole

Indexed keywords

ANTIOXIDANT; CASPASE 3; CASPASE 7; EYE PROTECTIVE AGENT; HYDROGEN PEROXIDE; HYDROXYL RADICAL; NITRONE DERIVATIVE; PHENYL N TERTBUTYLNITRONE; PRAMIPEXOLE; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE;

A WAVE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; ELECTRORETINOGRAM; ENZYME ACTIVATION; EYE PROTECTION; FENTON REACTION; HYDROXYL RADICAL SCAVENGING ASSAY; IN VITRO STUDY; LIGHT EXPOSURE; LIGHT INDUCED RETINAL DAMAGE; MALE; MOUSE; NONHUMAN; PHOTORECEPTOR INNER SEGMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA INJURY; RETINA ROD OUTER SEGMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUNEL ASSAY; ADVERSE EFFECTS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; ELECTRORETINOGRAPHY; GENETICS; LIGHT; PATHOLOGY; PHOTORECEPTOR CELL; RETINAL DEGENERATION;

ANIMALS; APOPTOSIS; BENZOTHIAZOLES; CELL DEATH; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; IN SITU NICK-END LABELING; LIGHT; MALE; MICE; MICE, INBRED BALB C; PHOTORECEPTOR CELLS, VERTEBRATE; RETINAL DEGENERATION;

EID: 84938705134     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.07.007     Document Type: Article

References (55)

1. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001, 119:1417-1436.
2. Bird A.C., Phillips R.L., Hageman G.S. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014, 132:338-345.
3. Boatright K.M., Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15:725-731.
4. Bowes Rickman C., Farsiu S., Toth C.A., Klingeborn M. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest. Ophthalmol. Vis. Sci. 2013, 54. ORSF68-80.
5. Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 1998, 71:295-301.
6. Clarke C.E., Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002, 360:1767-1769.
7. Cruickshanks K.J., Klein R., Klein B.E. Sunlight and age-related macular degeneration. The Beaver dam eye study. Arch. Ophthalmol. 1993, 111:514-518.
8. Delcourt C., Diaz J.L., Ponton-Sanchez A., Papoz L. Smoking and age-related macular degeneration. The POLA study. Pathologies Oculaires Liees a l'Age. Arch. Ophthalmol. 1998, 116:1031-1035.
9. Derouiche A., Asan E. The dopamine D2 receptor subfamily in rat retina: ultrastructural immunogold and in situ hybridization studies. Eur. J. Neurosci. 1999, 11:1391-1402.
10. Dorey C.K., Wu G., Ebenstein D., Garsd A., Weiter J.J. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest. Ophthalmol. Vis. Sci. 1989, 30:1691-1699.
11. Dunaief J.L., Dentchev T., Ying G.S., Milam A.H. The role of apoptosis in age-related macular degeneration. Arch. Ophthalmol. 2002, 120:1435-1442.
12. Eldred G.E., Lasky M.R. Retinal age pigments generated by self-assembling lysosomotropic detergents. Nature 1993, 361:724-726.
13. Fujita Y., Izawa Y., Ali N., Kanematsu Y., Tsuchiya K., Hamano S., Tamaki T., Yoshizumi M. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn. Schmiedeb. Arch. Pharmacol. 2006, 372:257-266.
14. Hahn P., Milam A.H., Dunaief J.L. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch. Ophthalmol. 2003, 121:1099-1105.
15. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., VonVoigtlander P.F. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 1996, 742:80-88.
16. Hartnett M.E., Elsner A.E. Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. Ophthalmology 1996, 103:58-71.
17. Holz F.G., Bellmann C., Margaritidis M., Schutt F., Otto T.P., Volcker H.E. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:145-152.
18. Imai S., Inokuchi Y., Nakamura S., Tsuruma K., Shimazawa M., Hara H. Systemic administration of a free radical scavenger, edaravone, protects against light-induced photoreceptor degeneration in the mouse retina. Eur. J. Pharmacol. 2010, 642:77-85.
19. Imai S., Shimazawa M., Nakanishi T., Tsuruma K., Hara H. Calpain inhibitor protects cells against light-induced retinal degeneration. J. Pharmacol. Exp. Ther. 2010, 335:645-652.
20. Inden M., Kitamura Y., Tamaki A., Yanagida T., Shibaike T., Yamamoto A., Takata K., Yasui H., Taira T., Ariga H., Taniguchi T. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem. Int. 2009, 55:760-767.
21. Inokuchi Y., Imai S., Nakajima Y., Shimazawa M., Aihara M., Araie M., Hara H. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo. J. Pharmacol. Exp. Ther. 2009, 329:687-698.
22. Jeong M.H., Yang K.M., Jeong D.H., Lee C.G., Oh S.J., Jeong S.K., Lee K.W., Jo Y.R., Jo W.S. Protective activity of a novel resveratrol analogue, HS-1793, against DNA damage in 137Cs-irradiated CHO-K1 cells. J. Radiat. Res. 2014, 55:464-475.
23. Jiang C.P., Ding H., Shi D.H., Wang Y.R., Li E.G., Wu J.H. Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells. World J. Gastroenterol. 2012, 18:1753-1764.
24. Kaarniranta K., Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J. Mol. Med. Berl. 2009, 87:117-123.
25. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., Taniguchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 2001, 417:59-67.
26. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., Taniguchi T. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 1998, 54:1046-1054.
27. Kovach J.L., Schwartz S.G., Flynn H.W., Scott I.U. Anti-VEGF treatment strategies for wet AMD. J. Ophthalmol. 2012, 2012:786870.
28. Li C., Guo Y., Xie W., Li X., Janokovic J., Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem. Res. 2010, 35:1546-1556.
29. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
30. Masutomi K., Chen C., Nakatani K., Koutalos Y. All-trans retinal mediates light-induced oxidation in single living rod photoreceptors. Photochem. Photobiol. 2012, 88:1356-1361.
31. O'Driscoll C., Doonan F., Sanvicens N., Messeguer A., Cotter T.G. A novel free radical scavenger rescues retinal cells in vivo. Exp. Eye Res. 2011, 93:65-74.
32. Pattee G.L., Post G.R., Gerber R.E., Bennett J.P. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2003, 4:90-95.
33. Ramirez A.D., Wong S.K., Menniti F.S. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur. J. Pharmacol. 2003, 475:29-35.
34. Ranchon I., Chen S., Alvarez K., Anderson R.E. Systemic administration of phenyl-N-tert-butylnitrone protects the retina from light damage. Invest. Ophthalmol. Vis. Sci. 2001, 42:1375-1379.
35. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., Mariotti S.P. Global data on visual impairment in the year 2002. Bull. World Health Organ. 2004, 82:844-851.
36. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y., Group M.S. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
37. Roth C., Pantel K., Muller V., Rack B., Kasimir-Bauer S., Janni W., Schwarzenbach H. Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer 2011, 11:4.
38. Rozanowska M., Jarvis-Evans J., Korytowski W., Boulton M.E., Burke J.M., Sarna T. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J. Biol. Chem. 1995, 270:18825-18830.
39. Seddon J.M., Reynolds R., Yu Y., Daly M.J., Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011, 118:2203-2211.
40. Shen J.K., Dong A., Hackett S.F., Bell W.R., Green W.R., Campochiaro P.A. Oxidative damage in age-related macular degeneration. Histol. Histopathol. 2007, 22:1301-1308.
41. Shimazaki H., Hironaka K., Fujisawa T., Tsuruma K., Tozuka Y., Shimazawa M., Takeuchi H., Hara H. Edaravone-loaded liposome eyedrops protect against light-induced retinal damage in mice. Invest. Ophthalmol. Vis. Sci. 2011, 52:7289-7297.
42. Song H., Wohltmann M., Tan M., Ladenson J.H., Turk J. Group VIA phospholipase A2 mitigates palmitate-induced beta-cell mitochondrial injury and apoptosis. J. Biol. Chem. 2014, 289:14194-14210.
43. Spencer M.L., Shao H., Andres D.A. Induction of neurite extension and survival in pheochromocytoma cells by the Rit GTPase. J. Biol. Chem. 2002, 277:20160-20168.
44. Tanito M., Elliott M.H., Kotake Y., Anderson R.E. Protein modifications by 4-hydroxynonenal and 4-hydroxyhexenal in light-exposed rat retina. Invest. Ophthalmol. Vis. Sci. 2005, 46:3859-3868.
45. Tanito M., Nishiyama A., Tanaka T., Masutani H., Nakamura H., Yodoi J., Ohira A. Change of redox status and modulation by thiol replenishment in retinal photooxidative damage. Invest. Ophthalmol. Vis. Sci. 2002, 43:2392-2400.
46. Tanito M., Yoshida Y., Kaidzu S., Ohira A., Niki E. Detection of lipid peroxidation in light-exposed mouse retina assessed by oxidative stress markers, total hydroxyoctadecadienoic acid and 8-iso-prostaglandin F2alpha. Neurosci. Lett. 2006, 398:63-68.
47. Tomita H., Kotake Y., Anderson R.E. Mechanism of protection from light-induced retinal degeneration by the synthetic antioxidant phenyl-N-tert-butylnitrone. Invest. Ophthalmol. Vis. Sci. 2005, 46:427-434.
48. Tsuruma K., Tanaka Y., Shimazawa M., Mashima Y., Hara H. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels. Mol. Vis. 2011, 17:3556-3565.
49. Ueki Y., Wang J., Chollangi S., Ash J.D. STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage. J. Neurochem. 2008, 105:784-796.
50. Yamashita H., Horie K., Yamamoto T., Nagano T., Hirano T. Light-induced retinal damage in mice. Hydrogen peroxide production and superoxide dismutase activity in retina. Retina 1992, 12:59-66.
51. Yokoyama K., Oiwa Y., Imanishi R., Shimasaki M., Kishimoto W., Ozaki N., Igarashi T. Studies on the metabolic fate of pramipexole (SND 919 CL2Y) (I): absorption, distribution and Excretion after a single oral administration to rats. Xenobio. Metabol. Dispos. 1999, 14:300-308.
52. Yoneda S., Tanaka E., Goto W., Ota T., Hara H. Topiramate reduces excitotoxic and ischemic injury in the rat retina. Brain Res. 2003, 967:257-266.
53. Yu Y., Reynolds R., Rosner B., Daly M.J., Seddon J.M. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest. Ophthalmol. Vis. Sci. 2012, 53:1548-1556.
54. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 1999, 154:1423-1429.
55. Zou L., Xu J., Jankovic J., He Y., Appel S.H., Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 2000, 281:167-170.